SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Metallofullerene nanoparticles to circumvent cisplatin resistance in cancer	Combining nontoxic metallofullerene nanoparticles with cisplatin could help circumvent cisplatin resistance and treat cancer. The combination therapy decreased cisplatin-resistant human prostate cancer cell viability by about 30% compared with cisplatin or nanoparticle treatment alone. In a mouse model of cisplatin-resistant human prostate cancer, the combination reduced tumor growth compared with cisplatin or nanoparticle treatment alone. Next steps could include evaluating the combination of the metallofullerene nanoparticle with other chemotherapeutics in cell and animal cancer models. *SciBX* 3(16); doi:10.1038/scibx.2010.510 Published online April 22, 2010	Patent and licensing status unavailable	Liang, X.-J. *et al. Proc. Natl. Acad. Sci. USA*; published online April 5, 2010; doi:10.1073/pnas.0909707107 **Contact:** Yuliang Zhao, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, China e-mail: zhaoyuliang@mail.ihep.ac.cn **Contact:** Xing-Jie Liang, National Center for Nanoscience and Technology of China, Beijing, China e-mail: liangxj@nanoctr.cn